Researchers refine understanding of fetal hemoglobin regulation

Credit: CC0 Public Domain

Researchers at Children's Hospital of Philadelphia (CHOP) have discovered a new part of the regulatory cascade responsible for silencing fetal hemoglobin in adult cells. The findings, published today in Nature Genetics, refine scientists' understanding of the process that turns fetal hemoglobin "off" and adult hemoglobin "on," which could have therapeutic implications for those with blood disorders like sickle cell disease and beta-thalassemia.

When babies are in utero, the gamma-globin gene produces , but after birth, this gene is switched off and the beta-globin gene is turned on, producing , a protein in red blood cells that carries oxygen from the lungs to tissues throughout the body.

Patients with and beta-thalassemia have mutations in the beta-globin gene, which leads to mutant adult hemoglobin production and serious health complications, ranging from delayed growth to chronic pain and stroke. Since these patients have functional but silenced gamma globin genes, there has been interest among researchers in exploring the therapeutic potential of reversing the switch from fetal to adult hemoglobin. In fact, the reversal of this hemoglobin switch has been a major goal over the last several decades.

However, doing so requires identifying and exploiting factors responsible for this transition, the underlying mechanism of which is not fully understood. Prior research has identified transcription factor BCL11A as a major repressor of fetal hemoglobin genes. The BCL11A gene, which is also a target for recent gene therapy approaches, is not expressed in fetal red cell precursors and is turned on only in adult type . There has been debate as to whether the BCL11A gene is primarily regulated at the transcriptional or post-transcriptional level. Moreover, how transcriptional regulation of the BCL11A gene occurs is unknown.

CHOP researchers in the Blobel Lab, led by Research Associate Peng Huang, Ph.D., demonstrated that the developmental regulation of the BCL11A gene occurs predominantly at the transcriptional level. Using a CRISPR-based genetic screen, they identified the transcriptional repressor HIC2, which is expressed in the fetal stage, as a repressor of BCL11A transcription in fetal cells. The researchers also showed that overexpressing HIC2 strongly increased production of fetal hemoglobin.

Further experiments demonstrated that HIC2 regulates the fetal-to-adult hemoglobin switch by occupying developmental regulatory elements in the BCL11A gene. Ultimately, HIC2 is downregulated through a developmental process in , enabling the expression of BCL11A and subsequent silencing of fetal hemoglobin.

"Our study uncovered HIC2 as a key regulator of the fetal-to-adult hemoglobin transition," said senior study author Gerd A. Blobel, MD, Ph.D., an investigator and holder of the Frank E. Weise III Endowed Chair in Pediatric Hematology at Children's Hospital of Philadelphia. "Although it is likely that additional fetal stage-specific are involved in maintaining the cells in a fetal state, this study provides important insights into the silencing of fetal , which could potentially be targeted in future therapies."

Explore further

Researchers identify novel factors involved in silencing fetal hemoglobin

More information: Peng Huang, HIC2 controls developmental hemoglobin switching by repressing BCL11A transcription, Nature Genetics (2022). DOI: 10.1038/s41588-022-01152-6.
Journal information: Nature Genetics

Provided by The Children’s Hospital of Philadelphia
Citation: Researchers refine understanding of fetal hemoglobin regulation (2022, August 8) retrieved 28 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors